Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- NASDAQ OMX and Leerink Swann to Co-Host HealthCare Industry Forum
Dec 04, 2008 09:34 AM
- Javelin Pharmaceuticals Announces 15 Percent Reduction in Workforce
Nov 14, 2008 10:08 AM
- Javelin Pharmaceuticals, Inc. Reports Third Quarter 2008 Results and Corporate Highlights
Nov 10, 2008 07:29 AM
- Javelin Pharmaceuticals to Review Third Quarter 2008 Financial Results
Nov 06, 2008 07:43 AM
- Javelin Pharmaceuticals Appoints Dr. Eric Lang Vice President of Clinical Research
Oct 20, 2008 07:46 AM
- Analyst Reports for Texas Instruments Incorporated, Lincoln National Corporation, Valley National Bancorp and Javelin Pharmaceuticals Inc.
Oct 10, 2008 01:17 PM
- Javelin Enrolls First Patient in an Open Label Safety Study of Dyloject(TM)
Sep 22, 2008 07:49 AM
- Javelin Pharmaceuticals to Present at the 2008 UBS Global Life Sciences Conference
Sep 17, 2008 08:31 AM
- Javelin Pharmaceuticals Completes Patient Enrollment for Second of two Pivotal Phase 3 Studies of Dyloject(TM)
Sep 16, 2008 08:19 AM
- Company Profile for Javelin Pharmaceuticals, Inc.
Aug 29, 2008 10:41 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
JAV
|
Compare to S&P
|
| YTD |
-85.29 %
|
-0.01 %
|
| 4 Weeks |
-52.99 %
|
-48.56 %
|
| 12 Weeks |
-78.85 %
|
-70.07 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -12.50 %
|
|
EPS Growth in Last Year: -5.88 %
|
|
Sales Growth in Last Quarter: -99.80 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
